BioCentury | Feb 25, 2021
Finance

$135M series C buys Vividion flexibility to explore broad pipeline

...$230 million series B by Flagship Pioneering’s gene writing play Tessera Therapeutics Inc., co-led by SoftBank Vision Fund...
BioCentury | Jan 13, 2021
Deals

Jan. 12 Quick Takes: $230M series B for Flagship’s ‘gene writer’ Tessera; plus Elucida, Vedanta, AbbVie-Dragonfly, Primmune

...million series B round co-led by Alaska Permanent Fund Corporation, Altitude Life Science Ventures and SoftBank Vision Fund...
BioCentury | Dec 10, 2020
Finance

Dec. 9 Quick Takes: Nuance leads bolus of venture rounds for China’s innovators; plus launches for Hillhouse’s Overland, OSI’s PepGen and Atlas’ Vigil and more

...play Pear Pear Therapeutics Inc. raised $80 million in a series D financing led by SoftBank Vision Fund...
BioCentury | Sep 29, 2020
Financial News

Sept. 28 Quick Takes: Biogen gains $1.4B on aducanumab update; plus Zai, XtalPi, InventisBio, Galecto, Innovent, Galapagos-Gilead, Biocytogen and ACT Accelerator

...in a series C round led by SoftBank Vision Fund...
BioCentury | Jul 23, 2020
Product Development

Encoded to drive first gene therapy into clinic with GV-led $135M series D

...Capital, HBM Genomics and Menlo Ventures. New investors included Meritech Capital, Farallon Capital Management, and Softbank Vision Fund...
BioCentury | Jul 16, 2020
Finance

Relay’s IPO among the year’s largest for a biotech as others wait in wings

...Near Starting Line” ). The deal and first-day stock move suggests a strong return for SoftBank Vision Fund...
BioCentury | Feb 25, 2020
Finance

Karius looks to $165M B round to spur growth of diagnostic business

...a series B to grow its customer base and advance its DNA-based blood test technology. SoftBank Vision Fund...
BioCentury | Jan 22, 2020
Emerging Company Profile

Relay’s protein motion platform approaches clinical starting line

...Investors: Third Rock Ventures, D.E. Shaw Research, GV, Section 32, Casdin Capital, EcoR1 Capital, BVF, SoftBank Vision Fund...
BioCentury | Oct 11, 2019
Financial News

Vir’s aftermarket weakness adds to skittishness for IPO queue

...or roughly 3.4x the $160 million commitment in the two rounds. Its second-largest shareholder, Softbank Vision Fund...
BioCentury | Sep 4, 2019
Financial News

Vir plots IPO as more programs near clinic

...million in cash at June 30. Top shareholders include Arch Venture Partners with 27% and SoftBank Vision Fund...
Items per page:
1 - 10 of 24
BioCentury | Feb 25, 2021
Finance

$135M series C buys Vividion flexibility to explore broad pipeline

...$230 million series B by Flagship Pioneering’s gene writing play Tessera Therapeutics Inc., co-led by SoftBank Vision Fund...
BioCentury | Jan 13, 2021
Deals

Jan. 12 Quick Takes: $230M series B for Flagship’s ‘gene writer’ Tessera; plus Elucida, Vedanta, AbbVie-Dragonfly, Primmune

...million series B round co-led by Alaska Permanent Fund Corporation, Altitude Life Science Ventures and SoftBank Vision Fund...
BioCentury | Dec 10, 2020
Finance

Dec. 9 Quick Takes: Nuance leads bolus of venture rounds for China’s innovators; plus launches for Hillhouse’s Overland, OSI’s PepGen and Atlas’ Vigil and more

...play Pear Pear Therapeutics Inc. raised $80 million in a series D financing led by SoftBank Vision Fund...
BioCentury | Sep 29, 2020
Financial News

Sept. 28 Quick Takes: Biogen gains $1.4B on aducanumab update; plus Zai, XtalPi, InventisBio, Galecto, Innovent, Galapagos-Gilead, Biocytogen and ACT Accelerator

...in a series C round led by SoftBank Vision Fund...
BioCentury | Jul 23, 2020
Product Development

Encoded to drive first gene therapy into clinic with GV-led $135M series D

...Capital, HBM Genomics and Menlo Ventures. New investors included Meritech Capital, Farallon Capital Management, and Softbank Vision Fund...
BioCentury | Jul 16, 2020
Finance

Relay’s IPO among the year’s largest for a biotech as others wait in wings

...Near Starting Line” ). The deal and first-day stock move suggests a strong return for SoftBank Vision Fund...
BioCentury | Feb 25, 2020
Finance

Karius looks to $165M B round to spur growth of diagnostic business

...a series B to grow its customer base and advance its DNA-based blood test technology. SoftBank Vision Fund...
BioCentury | Jan 22, 2020
Emerging Company Profile

Relay’s protein motion platform approaches clinical starting line

...Investors: Third Rock Ventures, D.E. Shaw Research, GV, Section 32, Casdin Capital, EcoR1 Capital, BVF, SoftBank Vision Fund...
BioCentury | Oct 11, 2019
Financial News

Vir’s aftermarket weakness adds to skittishness for IPO queue

...or roughly 3.4x the $160 million commitment in the two rounds. Its second-largest shareholder, Softbank Vision Fund...
BioCentury | Sep 4, 2019
Financial News

Vir plots IPO as more programs near clinic

...million in cash at June 30. Top shareholders include Arch Venture Partners with 27% and SoftBank Vision Fund...
Items per page:
1 - 10 of 24